ReviewDrugs in context2024
Invasive fungal infections in critically ill children: epidemiology, risk factors and antifungal drugs.
Review in Drugs in context, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Clinical Characteristics of Carbapenem-Resistant Gram-Negative Bloodstream Infections and Fungemia Among High-Risk Pediatric Patients Receiving Empirical Antifungal Therapy.Pathogens (Basel, Switzerland) · 2026Observational
- Activity of Isavuconazole and Comparator Agents Against Pediatric Isolates From Invasive Fungal Infections.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation Following Recent Invasive Mold Disease in Pediatric Patients.Journal of fungi (Basel, Switzerland) · 2026Article
- Predictive Utility of the Pediatric-EQUAL Scale in Pediatric Candidemia Admitted to PICU Association with Clinical and Microbiological Factors Related Mortality.Infectious diseases and therapy · 2026Article
- Antifungal Stewardship in the Pediatric Intensive Care Unit: Time is of the Essence.Infection and drug resistance · 2026Review
- Secondary invasive aspergillosis following severeIDCases · 2026Article
- Antibiotic treatment for neonatal sepsis: changing trends and future directions.Drugs in context · 2026Review
- The global landscape of pediatric monoclonal antibody (mAb) clinical trials: an analysis of ClinicalTrials.gov.Frontiers in pediatrics · 2026Article
- Diagnosis and treatment of invasive fungal disease in children with hematological malignancies after chemotherapy: Challenges and strategies (Review).Experimental and therapeutic medicine · 2026Review
- Trends in Pediatric Invasive Candidiasis: Shifting Species Distribution and Improving Outcomes.Mycopathologia · 2025Article
- Invasive Fungal Disease After Chimeric Antigen Receptor-T Immunotherapy in Adult and Pediatric Patients.Pathogens (Basel, Switzerland) · 2025Review
- Risk factors for identifying pulmonary aspergillosis in pediatric patients.Frontiers in cellular and infection microbiology · 2025Article
- Prognostic factors of invasive fungal infections in pediatric intensive care units and changes in treatment outcomes before and after the COVID-19 pandemic: a multicenter retrospective study.Frontiers in microbiology · 2025Article
- The Significance of Mono- and Dual-Effective Agents in the Development of New Antifungal Strategies.Chemical biology & drug design · 2025Review
- The kinase Bud32 regulates iron homeostasis in fungal pathogenFrontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Invasive fungal infections (IFIs) are important infectious complications amongst critically ill children. The most common fungal infections are due to Methods: A PubMed search was conducted with Clinical Queries using the key terms "antifungal", "children", "critical care" AND "paediatric intensive care unit" OR "PICU". The search strategy included clinical trials, randomized controlled trials, meta-analyses, observational studies and reviews and was limited to the English literature in paediatrics. Results: Conclusions: Antifungal agents are highly efficacious. For successful treatment outcomes, it is crucial to determine the optimal dosage, monitor pharmacokinetics parameters and adverse effects, and individualized therapeutic monitoring. Despite potent antifungal medications, ICIs and IAIs continue to be serious infections with high mortality rates. Pre-emptive therapy has been used for IAIs. Most guidelines recommend voriconazole as initial therapy of invasive aspergillosis in most patients, with consideration of combination therapy with voriconazole plus an echinocandin in selected patients with severe disease. The challenge is to identify critically ill patients at high risks of ICIs for targeted prophylaxis. Intravenous/per os fluconazole is first-line pre-emptive treatment for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.